Numis Securities Reiterates “Buy” Rating for Abzena (ABZA)
Abzena (LON:ABZA)‘s stock had its “buy” rating reaffirmed by investment analysts at Numis Securities in a research note issued on Wednesday. They presently have a GBX 80 ($1.08) target price on the stock. Numis Securities’ target price would suggest a potential upside of 149.84% from the company’s previous close.
Separately, FinnCap reissued a “buy” rating and set a GBX 70 ($0.94) price target on shares of Abzena in a report on Monday.
Abzena (ABZA) traded down GBX 0.98 ($0.01) on Wednesday, reaching GBX 32.02 ($0.43). The company had a trading volume of 2,346 shares, compared to its average volume of 123,688. Abzena has a fifty-two week low of GBX 27.73 ($0.37) and a fifty-two week high of GBX 66 ($0.89).
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Stock Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related stocks with our FREE daily email newsletter.